Cell and gene therapies in managed care: US payer insights on coverage and financial risk.
Payers recognize the potential of cell and gene therapies but are hindered by high costs and uncertainty about their long-term effectiveness.
Where it sits
this study against the rest of the mgf (mechano growth factor) corpusSummary and findings
This study assessed US payer perspectives on the reimbursement of cell and gene therapies (CGTs) through interviews with decision-makers. It highlighted barriers such as high upfront costs and uncertainty regarding long-term benefits. The findings suggest a need for innovative payment models to facilitate CGT adoption.
Abstract
<h4>Aims</h4>Cell and gene therapies (CGTs) are increasingly transforming the treatment of serious and life-threatening conditions, offering durable and, in some cases, potentially curative benefit. However, high upfront costs paired with the expectation for long-term value realization create misalignment with conventional managed care and reimbursement models. Although innovative payment and risk-sharing strategies have been proposed, adoption remains limited. Understanding how payers are navigating these challenges is increasingly critical as CGTs continue to transition into established standards of care.<h4>Methods</h4>Sixty-minute, double-anonymized, semi-structured interviews were conducted to assess United States (US) payer perspectives toward CGT reimbursement. Participants were recruited <i>via</i> third-party vendors to minimize bias. Data collection included Likert-scale ratings and open-ended inquiries regarding access, formulary processes, and reimbursement frameworks.<h4>Results</h4>Twenty payer decision-makers were interviewed. While 17 viewed CGTs as among the most important medical innovations of our time, 18 agreed that the US healthcare system is not adequately prepared for broad CGT adoption. Top barriers to reimbursement include high upfront costs and long-term durability uncertainty. Preferred mitigation strategies include reinsurance/stop-loss and risk pools. Member portability and data tracking remain primary barriers to innovative payment models.<h4>Limitations</h4>Sample size may not represent all US payers. Qualitative study findings identify trends and consensus only.<h4>Conclusions</h4>Payers acknowledge the significant clinical promise of CGTs, but high upfront costs and long-term durability uncertainty continue to complicate coverage strategies and limit broader adoption. Ongoing evaluation of reimbursement frameworks, financing strategies, and emerging long-term evidence may help characterize how coverage and payment models evolve as the CGT landscape expands.
Background
This paper addresses the challenges of reimbursement for cell and gene therapies (CGTs) in the US healthcare system. Prior knowledge indicates that CGTs have the potential for significant clinical benefits but face hurdles in adoption due to financial and structural issues. Understanding payer perspectives is crucial as CGTs become more integrated into standard care.
Methods
The study utilized sixty-minute, double-anonymized, semi-structured interviews with 20 payer decision-makers. Participants were recruited via third-party vendors to minimize bias. Data collection included Likert-scale ratings and open-ended inquiries focused on access, formulary processes, and reimbursement frameworks.
Results
The study found that 17 out of 20 participants viewed CGTs as significant innovations, while 18 believed the current healthcare system is unprepared for their widespread adoption. Key barriers identified were high upfront costs and uncertainty regarding long-term durability of CGTs.
Interpretation
The findings align with existing literature that highlights financial barriers to CGT adoption. While the statistical significance of the perspectives is noted, the clinical significance remains uncertain due to the qualitative nature of the study. Limitations such as the small sample size and qualitative design may affect the generalizability of the conclusions.
Key findings
- 20 payer decision-makers interviewed.
- 17 viewed CGTs as among the most important medical innovations.
- 18 agreed that the US healthcare system is not adequately prepared for CGT adoption.
- Top barriers include high upfront costs and long-term durability uncertainty.
Limitations
- Sample size may not represent all US payers.
- Qualitative study findings identify trends and consensus only.